膀胱癌免疫治疗相关肿瘤微环境及其在人和小鼠肿瘤中的组成特征初探

doi:10.3969/j.issn.1009-976X.2022.02.006

摘要/Abstract

摘要： 目的应用生物信息学分析鉴定膀胱癌免疫治疗中起关键作用的肿瘤微环境（TME）组成特征,初步分析这些组分在人膀胱癌组织和BBN（N-butyl-N-（4-hydroxybutyl）-nitrosamine）诱导的自发小鼠膀胱肿瘤中表型的相似性。方法分析晚期膀胱癌PD-L1阻断治疗IMvigor210数据集,利用DESeq2筛选与疗效相关的差异基因,通过GO和KEGG通路富集分析找出差异富集的通路;采用IOBR分析TME中的细胞浸润特征。通过TCGA数据库分析差异浸润细胞基因集与膀胱癌预后和分期的关系,在我院32例膀胱癌组织标本中进行免疫组化验证。建立BBN诱导的自发小鼠膀胱肿瘤模型,通过H&E染色和免疫组化对BBN诱导的自发小鼠膀胱肿瘤和人膀胱癌进展相似性及其TME主要组分进行比较。结果在IMvigor210数据集中存在521个与免疫治疗疗效相关的差异基因,其中44个差异基因富集在含胶原细胞外基质上,提示成纤维细胞与免疫治疗疗效相关。TME分析发现细胞周期、组蛋白等肿瘤细胞基因集与NK细胞、CD8⁺ T细胞基因集在膀胱癌免疫治疗有效组中富集,而炎症性肿瘤相关成纤维细胞基因集在免疫治疗无效组中富集。TCGA分析显示：NK细胞和CD8⁺ T细胞基因集与膀胱癌患者总体生存时间呈正相关,CD56表达与膀胱癌病理分期呈正相关;PDGFRB表达与膀胱癌病理分期呈正相关。相比于低分期膀胱癌,PDGFRB⁺成纤维细胞在高分期膀胱癌中数量更多。在BBN小鼠模型中,BBN诱导的自发小鼠膀胱肿瘤发生率随着诱导时间逐渐升高,最终发展为肌层浸润性膀胱癌。免疫组化染色显示：小鼠和人膀胱肿瘤的TME中NK细胞和CD8⁺ T细胞以及成纤维细胞的浸润特征相似。结论本研究结合生信分析和免疫组化评分发现：膀胱癌中NK细胞、CD8⁺ T细胞和成纤维细胞与免疫治疗疗效和预后具有相关性;这些细胞在BBN诱导的自发小鼠膀胱肿瘤与人膀胱癌组织中的浸润表型相似。这些结果可为研究膀胱癌免疫治疗的机制提供理论依据和动物模型。

关键词: 膀胱癌, 生物信息学, 肿瘤微环境, 肿瘤相关成纤维细胞, BBN诱导的自发小鼠膀胱肿瘤模型

Abstract: Objective To identify the composition of the tumor microenvironment （TME） for the efficacy of bladder cancer immunotherapy in public databases and to evaluate their expression and distribution in human bladder cancers and N-butyl-N-（4-hydroxybutyl）-nitrosamine （BBN）-driven spontaneous mouse bladder tumors. Methods IMvigor210 database is a clinical trial for PD-L1 blockade treatment in advanced bladder cancer. We used DESeq2 to screen out differentially expressing genes （DEGs） that are associated with immunotherapy efficacy in IMvigor210 database. The differentially enriched pathways were further identified by GO and KEGG pathway enrichment analysis. IOBR R package was utilized to identify the cell composition in the TME. The clinical significance of differential cells gene signatures or associated gene expression were evaluated in TCGA bladder cancer database. By using 32 bladder cancer specimens from Sun Yat-sen Memorial Hospital, these cell infiltrations were confirmed by immunohistochemistry and associated with tumor stage. Furthermore, we established a BBN-driven spontaneous mouse bladder tumor model. H&E staining and immunohistochemistry were applied to compare the similarity of tumor progression and major composition of TME between mouse bladder tumor and human bladder cancer. Results In the IMvigor210 database, 521 DEGs were identified to be associated with efficacy of immunotherapy. Forty-four DEGs of them were enriched in collagen-containing extracellular matrix, suggesting that fibroblasts were engaged in the efficacy of immunotherapy. TME analysis showed that gene sets of histones or cell cycle, NK cells and CD8⁺ T cells gene signatures were enriched in the effective group, while gene signatures of inflammatory cancer-associated fibroblasts were enriched in the ineffective group. In the TCGA bladder cancer database, NK cells and CD8⁺ T cells gene signatures were positively associated with good prognosis of patients, while CD56 expression was positively associated with tumor stage. By contrast, PDGFRB expression was positively associated with poor prognosis and tumor stage. Moreover, PDGFRB⁺ cancer-associated fibroblasts were heavily infiltrated in high-stage bladder cancer tissues. In the BBN mouse model, increasing proportion of mice developed bladder tumors and ultimately into muscle-invasive bladder cancer （MIBC） in a time-dependent manner. BBN-driven mouse tumor recapitulated the histology and manifested similar disease progression to human bladder cancer. There were similar infiltration patterns of NK cells, CD8⁺ T cells and cancer-associated fibroblasts in mouse tumor and human bladder cancer. Conclusion Bioinformatics analysis showed that NK cells, CD8⁺ T cells and caner-associated fibroblasts are associated with the efficacy of immunotherapy and have clinical significance in human bladder cancer. The infiltration patterns of these cells were similar in human cancer and a spontaneous mouse tumor model. These results provide potential targets and a rational mouse model for further research on immunotherapy of bladder cancer.

Key words: bladder cancer, bioinformatics analysis, tumor microenvironment, cancer-associated fibroblast, BBN-driven spontaneous mouse bladder tumor

中图分类号:

R737.1

周炳坤, 王博, 贺情情, 黄孝东, 陈俊宇, 黄健. 膀胱癌免疫治疗相关肿瘤微环境及其在人和小鼠肿瘤中的组成特征初探[J]. 岭南现代临床外科, 2022, 22(02): 143-153.

ZHOU Bing-kun, WANG Bo, HE Qing-qing, HUANG Xiao-dong, CHEN Jun-yu, HUANG Jian. Tumor microenvironment for effective bladder cancer immunotherapy and its composition in human and mouse tumors: a preliminary report[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 143-153.

参考文献

[1] Kaufman DS, Shipley WU, Feldman AS.Bladder cancer[J]. Lancet, 2009,374(9685): 239-249.
[2] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
[3] Lenis AT, Lec PM, Chamie K, et al.Bladder Cancer: A Review[J]. JAMA, 2020,324(19): 1980-1991.
[4] Topalian SL, Hodi FS, Brahmer JR, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012,366(26): 2443-2454.
[5] Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J]. N Engl J Med, 2017,376(11): 1015-1026.
[6] Balar AV, Castellano D, O′Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017,18(11): 1483-1492.
[7] Powles T, O′Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study[J]. JAMA Oncol, 2017,3(9): e172411.
[8] Anderson NM, Simon MC.The tumor microenvironment[J]. Curr Biol, 2020,30(16): R921-r925.
[9] Petitprez F, Meylan M, de Reyniès A, et al. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies[J]. Front Immunol, 2020,11: 784.
[10] Binnewies M, Roberts EW, Kersten K, et al.Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018,24(5): 541-550.
[11] Cózar B, Greppi M, Carpentier S, et al.Tumor-Infiltrating Natural Killer Cells[J]. Cancer Discov, 2021,11(1): 34-44.
[12] Laumont CM, Banville AC, Gilardi M, et al.Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities[J]. Nat Rev Cancer, 2022.
[13] Ma X, Xiao L, Liu L, et al. CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability [J]. Cell Metab, 2021,33(5): 1001-1012.e1005.
[14] Helmink BA, Reddy SM, Gao J, et al.B cells and tertiary lymphoid structures promote immunotherapy response[J]. Nature, 2020,577(7791): 549-555.
[15] Tumeh PC, Harview CL, Yearley JH, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014,515(7528): 568-571.
[16] Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018,19(1): 40-50.
[17] Harper J, Sainson RC.Regulation of the anti-tumour immune response by cancer-associated fibroblasts[J]. Semin Cancer Biol, 2014,25: 69-77.
[18] Fiori ME, Di Franco S, Villanova L, et al.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance[J]. Mol Cancer, 2019,18(1): 70.
[19] O′Connell JT, Sugimoto H, Cooke VG, et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization[J]. Proc Natl Acad Sci U S A, 2011,108(38): 16002-16007.
[20] Balar AV, Galsky MD, Rosenberg JE, et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. The Lancet, 2017,389(10064): 67-76.
[21] Zeng D, Ye Z, Shen R, et al.IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures[J]. Front Immunol, 2021,12: 687975.
[22] Miyamoto H, Yang Z, Chen YT, et al.Promotion of bladder cancer development and progression by androgen receptor signals[J]. J Natl Cancer Inst, 2007,99(7): 558-568.
[23] 王博, 林建勋, 于浩, 等. CD8+ T细胞的分布特征及其与膀胱癌预后关系的研究[J]. 中华泌尿外科杂志, 2015, (7): 500-504.
[24] Raskov H, Orhan A, Christensen JP, et al.Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy[J]. Br J Cancer, 2021,124(2): 359-367.
[25] Raskov H, Orhan A, Salanti A, et al.Natural Killer Cells in Cancer and Cancer Immunotherapy[J]. Cancer Lett, 2021,520: 233-242.
[26] Gentles AJ, Newman AM, Liu CL, et al.The prognostic landscape of genes and infiltrating immune cells across human cancers[J]. Nat Med, 2015,21(8): 938-945.
[27] Goode EL, Block MS, Kalli KR, et al.Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer[J]. JAMA Oncol, 2017,3(12): e173290.
[28] Pernot S, Terme M, Radosevic-Robin N, et al.Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance[J]. Gastric Cancer, 2020,23(1): 73-81.
[29] Han S, Zhang C, Li Q, et al.Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma[J]. Br J Cancer, 2014,110(10): 2560-2568.
[30] Mahmoud SM, Paish EC, Powe DG, et al.Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer[J]. J Clin Oncol, 2011,29(15): 1949-1955.
[31] Galon J, Bruni D.Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019,18(3): 197-218.
[32] Sato E, Olson SH, Ahn J, et al.Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer[J]. Proc Natl Acad Sci U S A, 2005,102(51): 18538-18543.
[33] Schumacher K, Haensch W, Röefzaad C, et al.Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas[J]. Cancer Res, 2001,61(10): 3932-3936.
[34] Chen J, Zhong W, Yang M, et al.Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy[J]. Cancer Immunol Immunother, 2021,70(9): 2657-2668.
[35] Schumacher TN, Schreiber RD.Neoantigens in cancer immunotherapy[J]. Science, 2015,348(6230): 69-74.
[36] Lee JS, Ruppin E.Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1[J]. JAMA Oncol, 2019,5(11): 1614-1618.
[37] Chen X, Xu R, He D, et al.CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer[J]. Oncogene, 2021,40(43): 6223-6234.
[38] Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy [J]. Immunity, 2019,50(1): 195-211.e110.
[39] Lee H, Quek C, Silva I, et al.Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients[J]. Oncoimmunology, 2019,8(2): e1537581.
[40] Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, et al. A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients[J]. Cancer Immunol Res, 2019,7(7): 1162-1174.
[41] López-Soto A, Gonzalez S, Smyth MJ, et al.Control of Metastasis by NK Cells[J]. Cancer Cell, 2017,32(2): 135-154.
[42] Hsu J, Hodgins JJ, Marathe M, et al.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J]. J Clin Invest, 2018,128(10): 4654-4668.
[43] Prat A, Navarro A, Paré L, et al.Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma[J]. Cancer Res, 2017,77(13): 3540-3550.
[44] Mazzaschi G, Facchinetti F, Missale G, et al.The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC[J]. Lung Cancer, 2019,127: 153-163.
[45] Barry KC, Hsu J, Broz ML, et al.A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments[J]. Nat Med, 2018,24(8): 1178-1191.
[46] Mao X, Xu J, Wang W, et al.Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021,20(1): 131.
[47] Calon A, Lonardo E, Berenguer-Llergo A, et al.Stromal gene expression defines poor-prognosis subtypes in colorectal cancer[J]. Nat Genet, 2015,47(4): 320-329.
[48] Comito G, Giannoni E, Segura CP, et al.Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression[J]. Oncogene, 2014,33(19): 2423-2431.
[49] Frings O, Augsten M, Tobin NP, et al.Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling[J]. Am J Pathol, 2013,182(6): 2037-2047.
[50] Derynck R, Turley SJ, Akhurst RJ.TGFβ biology in cancer progression and immunotherapy[J]. Nat Rev Clin Oncol, 2021,18(1): 9-34.
[51] Chakravarthy A, Khan L, Bensler NP, et al.TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure[J]. Nat Commun, 2018,9(1): 4692.
[52] Barrett RL, Puré E.Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy[J]. eLife, 2020,9.
[53] Diaz-Montero CM, Finke J, Montero AJ.Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications[J]. Semin Oncol, 2014,41(2): 174-184.
[54] Ford K, Hanley CJ, Mellone M, et al.NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors[J]. Cancer Res, 2020,80(9): 1846-1860.
[55] Oliveira PA, Arantes-Rodrigues R, Vasconcelos-Nóbrega C.Animal models of urinary bladder cancer and their application to novel drug discovery[J]. Expert Opin Drug Discov, 2014,9(5): 485-503.
[56] Zuiverloon TCM, de Jong FC, Costello JC, et al. Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines[J]. Bladder Cancer, 2018,4(2): 169-183.
[57] Chan E, Patel A, Heston W, et al.Mouse orthotopic models for bladder cancer research[J]. BJU International, 2009,104(9): 1286-1291.
[58] Robertson AG, Kim J, Al-Ahmadie H, et al.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer[J]. Cell, 2018,174(4): 1033.
[59] Leblond MM, Tillé L, Nassiri S, et al.CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner[J]. Cancer Immunol Res, 2020,8(9): 1180-1192.
[60] Fantini D, Glaser AP, Rimar KJ, et al.A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer[J]. Oncogene, 2018,37(14): 1911-1925.